![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Teva Quits PhRMA As Financial, Policy Challenges Loom For The Brand/Generic Hybrid Giant :: Pink Sheet Teva Quits PhRMA As Financial, Policy Challenges Loom For The Brand/Generic Hybrid Giant :: Pink Sheet](https://pink.pharmaintelligence.informa.com/-/media/editorial/pink-sheet/2023/02/ps2302_teva-departs-phrma.jpg?rev=736d9f24ad784499b0974e0ff773712a)
Teva Quits PhRMA As Financial, Policy Challenges Loom For The Brand/Generic Hybrid Giant :: Pink Sheet
Teva Pharmaceuticals and IBM Partner to Build Global e-Health Solutions on the IBM Watson Health Cloud
![Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform | Business Wire Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform | Business Wire](https://mms.businesswire.com/media/20221114005344/en/739014/22/teva_RGB_JPEG.jpg)